Lilly Loses Round Over Depositions In Zyprexa MDL

Law360, New York (March 26, 2009, 12:00 AM EDT) -- A judge in charge of discovery in the multidistrict litigation over Eli Lilly & Co.'s anti-psychotic drug Zyprexa has denied the drug company's request for an order “for the benefit of wary physicians” that doctors can testify on patient records, ruling that Lilly cannot preempt disputes over future depositions.

In an order signed Tuesday in the U.S. District Court for the Eastern District of New York, Magistrate Judge Roann L. Mann rejected Lilly's request to advise potential prescriber-deponents as to how the company may use “de-identified”...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.